NEW YORK (GenomeWeb) – Rare-disease non-profit group the Castleman Disease Collaborative Network said today that it is partnering with Janssen Research and Development in a proteomics study of patients with Castleman disease.

Specifically, the partners hope to improve diagnosis and treatment of one of the three subsets of the disorder, called idiopathic multicentric Castleman disease (iMCD).They plan to measure approximately 1,300 analytes in more than 260 serum samples collected from 100 iMCD patients at various time points during active disease.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.